- Genprex Inc Global One Media Interview TranscriptJun 22, 2023
- Genprex Inc at Sidoti & Company May Micro-Cap Virtual Conference TranscriptMay 11, 2023
- Genprex Inc KOL Event: Novel Gene Therapy to Treat Type 1 Diabetes TranscriptApr 12, 2023
- Genprex Inc at LD Micro Main Event TranscriptOct 26, 2022
- Genprex Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 12, 2022
- Genprex Inc at LD Micro Invitational Conference (Virtual) TranscriptJun 08, 2022
- Genprex Inc at Noble Capital Markets Investor Conference (Virtual) TranscriptApr 20, 2022
- Genprex Inc at Benzinga Healthcare Small Cap Conference (Virtual) TranscriptSep 29, 2021
- Genprex Inc C-Suite Interview with Noble Capital Markets TranscriptApr 22, 2021
- Cell and Gene Meeting on Mesa - Genprex TranscriptJan 08, 2021
- Genprex launches new branding for its lead drug REQORSA in preparation for upcoming studies TranscriptNov 06, 2020
- Genprex (GNPX) Virtual Road Show with CEO Rodney Varner TranscriptSep 15, 2020
- Genprex (GNPX) Channelchek C-Suite Series, CEO Rodney Varner interview with Noble's Dr. Ahu Demir TranscriptAug 04, 2020
Genprex Inc KOL Event: Novel Gene Therapy to Treat Type 1 Diabetes Transcript
Good afternoon, everyone. I'm Rodney Warner, Chairman, President, and Chief Executive Officer of Genprex. On behalf of the Genprex team, I thank you for joining us for what I believe will be an engaging and dynamic discussion on the groundbreaking work being done in our gene therapy diabetes program with our academic collaborator, the University of Pittsburgh.
We are particularly excited about the preclinical data related to our program in type 1 diabetes that the University of Pittsburgh presented at the 16th International Conference on Advanced Technologies and Treatments for Diabetes, or ATTD, in Berlin in late February.
Before we begin, let me call your attention to the fact that throughout the course of today's program, we may be making forward-looking statements. Before relying on any such statements, please refer to the risk factors contained in our most recent annual report on Form 10-K filed with the SEC at the end of March.
I would also like to note that Genprex has a sponsored research agreement in place with
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)